NASDAQ OMX

RR Donnelley introduces its new MultiTrans® Translation Management System (TMS), with innovative features and a new user interface

6.6.2016 07:30 | NASDAQ OMX

Del

LONDON, 2016-06-06 07:30 CEST (GLOBE NEWSWIRE) --

R. R. Donnelley & Sons Company (Nasdaq:RRD), a world leader in multi-channel communications, announces the release of the MultiTrans 2017 TMS, its next-generation translation management system designed to help organizations localize their content more cost effectively.

MultiTrans 2017 includes innovative features for project management, translation editing, translation memory and terminology management, all delivered in a redesigned workflow. With just one click, users can see their projects, quotes, invoices and reports. 

Additionally, MultiTrans 2017 can be integrated with a larger number of 3rd party systems, allowing users to submit projects via their own content management system. Supported systems include AEM, Stibo, Documentum, SharePoint and WordPress. The Web Editor – now cross-browser and cross-platform – allows users to seamlessly operate within a secure online translating environment.

New deployment and integration options are available to give clients maximum flexibility. For example, Managed MultiTrans TMS provides clients access to a centralized, tailored Customer portal and to the expert linguistic services of RR Donnelley Language Solutions. In a secure, managed environment, clients enjoy full control over their projects and processes, as well as enhanced visibility of all their language services.  

“At a time when businesses around the world are entering new markets and engaging in omni-channel discussions with multiple audiences, organizations need technology to help them manage more content in more languages,” explains Tom Juhase, President, Financial Services Group at RR Donnelley. “MultiTrans 2017 TMS delivers meaningful innovations to better serve our clients across the globe.”

“This new wave of innovation from MultiTrans will play a key role in our clients’ translation processes,” adds Christophe Djaouani, Vice President and Managing Director of RR Donnelley Language Solutions. “Thanks to MultiTrans 2017, we are providing them with even more efficiency and ultimately making things easier for all users involved.”  

About RR Donnelley
RR Donnelley (Nasdaq:RRD) helps organizations communicate more effectively by working to create, manage, produce, distribute and process content on behalf of our customers. The company assists customers in developing and executing multichannel communication strategies that engage audiences, reduce costs, drive revenues and increase compliance. RR Donnelley's innovative technologies enhance digital and print communications to deliver integrated messages across multiple media to highly targeted audiences at optimal times for clients in virtually every private and public sector. Strategically located operations provide local service and responsiveness while leveraging the economic, geographic and technological advantages of a global organization.

For more information, and for RR Donnelley's Global Social Responsibility Report, visit the company's website at www.rrdonnelley.com.

About RR Donnelley Language Solutions
RR Donnelley Language Solutions is a leading, recognized and trusted localization brand supporting corporations across industries in over 140 languages. This global business entity of RR Donnelley provides a full range of linguistic products and services (including translation, interpreting, transcreation, multilingual typesetting, software localization, and voiceover) wrapped around its market-leading MultiTrans language technology.

For more information about RR Donnelley Language Solutions, visit our website at  www.rrdonnelley.com/languagesolutions.

About MultiTrans
MultiTrans is a modular translation management system (TMS) that centralizes and automates translation workflows, leverages translation memory, and unifies terminology across an organization and its communications. To remain at the cutting edge of TMS technology, MultiTrans teams across the globe continually strive to innovate and develop new solutions, including the development of new features and connectors, in order to best respond to their clients’ ever-evolving translation needs.

Use of Forward-Looking Statements
This news release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements contained in RR Donnelley's filings with the SEC. RR Donnelley disclaims any obligation to update or revise any forward-looking statements.

         Investor Contact:
         Dave Gardella, Senior Vice President Finance:
         Tel: +1 312-326-8155
         E-mail: david.a.gardella@rrd.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressemelding

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressemelding

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

Ascom Myco and Koutio Médipôle optimize care communications and responsiveness16.8.2017 08:00Pressemelding

Ascom Holding AG / Ascom Myco and Koutio Médipôle optimize care communications and responsiveness . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Enabled by the Ascom Myco smart device, the new Koutio Médipôle is realizing improved care delivery through seamless information flow from the point of care to anywhere. BAAR, Switzerland, Aug. 16, 2017 (GLOBE NEWSWIRE) -- The new Koutio Médipôle hospital in the New Caledonian capital Nouméa, located in the southwest Pacific Ocean, has optimized patient care communications and responsiveness for the new 645-bed facility by deploying Ascom Myco Wi-Fi devices to support clinician teams and Ascom Myco Wi-Fi/GSM handsets, used across paramedic teams. The Ascom solution is seamlessly aligned with clinical workflow and applications (nurs

VistaJet Harnesses the Power of the American Eclipse to Offer Customers a Rare Viewing Opportunity15.8.2017 18:40Pressemelding

VistaJet invites customers to fly in parallel with an astronomical anomaly NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, will be offering customers the opportunity to experience and chase the American Solar Eclipse, appearing for the first time in 99 years on August 21, 2017. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0c41d7d-7ad9-4a46-9d2d-dcc1148b4772 The coast-to-coast National Eclipse and astronomical phenomenon will be visible in the United States from approximately 10:15AM PST, with the sun disappearing behind the moon from the Oregon coast, passing through 14 states to South Carolina.  Without being in this 70-mile strip, Americans will not be able to see the sun eclipsed in totality. With unparalleled experience flying into and out of the hardest to reach destinations, VistaJet is offer

NGX Bio Raises $3 Million to Fund Growth of Its DNA Sequencing Marketplace15.8.2017 17:00Pressemelding

SAN FRANCISCO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round.  The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors. NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally.  Demand for sequencing services is growing exponentially.  NGX Bio's platform matches the sequencing needs of customers with providers who have available sequencing capacity.  Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio's online ordering tools.  NGX Bio offers these services through numerous and deep relationships with its

Hminers Launch the Most Powerful Cryptocurrency Mining Rigs with Unique Features15.8.2017 15:57Pressemelding

Hminers has just introduced three new mining rigs with extraordinary features. The company already has the unique distinction of delivering the first ever 10nm ASIC mining rig in the cryptocurrency market. MIAMI, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Hminers is delighted to announce the mega launch of three new products that will make cryptocurrency mining easy and efficient like never before. This Miami-based organization is one of the most trusted names in the cryptocurrency market with the distinction of creating the world's first 10 nm ASIC Chip. The company's three new products H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U are now up for sale at www.Hminers.com. As the difficulties in bitcoin mining have kept on increasing over the last few years, Hminers has embraced new principles to create multi algorithm based miners. Each of the three new products from the company is built and designed to operate under multiple algorithms and provide custome

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom